Zions Bancorporation N.A. Purchases 85 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Zions Bancorporation N.A. boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 55.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 239 shares of the medical research company’s stock after buying an additional 85 shares during the quarter. Zions Bancorporation N.A.’s holdings in IQVIA were worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of IQV. Synergy Asset Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at $33,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the fourth quarter valued at about $44,000. Versant Capital Management Inc grew its stake in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of IQVIA in the 4th quarter valued at about $60,000. Finally, UMB Bank n.a. boosted its holdings in IQVIA by 72.8% during the 4th quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 169 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the company. Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Barclays cut their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. UBS Group cut their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Down 0.3 %

IQV stock opened at $179.40 on Friday. IQVIA Holdings Inc. has a twelve month low of $176.74 and a twelve month high of $253.84. The firm has a market cap of $31.63 billion, a PE ratio of 23.92, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business has a 50 day moving average of $193.55 and a 200 day moving average of $206.91. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.